Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells

Veterinary Immunology and Immunopathology

Volumn 153, Issue 3-4, 2013, Pages 249-259

  Shin, Dong Jun ^a,b   Park, Ji Yun ^a   Jang, Youn Young ^b   Lee, Je Jung ^b   Lee, Youn Kyung ^b   Shin, Myung Geun ^c   Jung, Ji Youn ^a   Carson, William E ^d   Cho, Duck ^b,c   Kim, Sang Ki ^a,b  

^a Kongju National University   (South Korea)

^b Chonnam National University Research Institute of Medical Sciences   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Canine; Cytotoxic large granular lymphocytes; Cytotoxicity; Expansion; NK cells

Indexed keywords

CD11 ANTIGEN; CD11D ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANZYME B; HERMES ANTIGEN; MESSENGER RNA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY A; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; T CELL RECEPTOR ALPHA BETA CHAIN; T CELL RECEPTOR GAMMA DELTA CHAIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CYTOTOXIC LARGE GRANULAR LYMPHOCYTE; CYTOTOXICITY; EX VIVO STUDY; GENE; GENETICS; IMMUNOTHERAPY; LARGE GRANULAR LYMPHOCYTE; MORPHOLOGY; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; TUMOR CELL;

ANIMALS; ANTIGENS, CD56; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DOGS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; KILLER CELLS, NATURAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY A; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA;

EID: 84877062267     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2013.03.006     Document Type: Article

References (40)

1. Barten R., Torkar M., Haude A., Trowsdale J., Wilson M.J. Divergent and convergent evolution of NK-cell receptors. Trends Immunol. 2001, 22:52-57.
2. Bonkobara M., Saito T., Yamashita M., Tamura K., Yagihara H., Isotani M., Sato T., Washizu T. Blastic natural killer cell leukaemia in a dog--a case report. Vet. J. 2007, 174:659-662.
3. Bonkobara M., Sato T., Takahashi N., Kasahara Y., Yagihara H., Tamura K., Isotani M., Azakami D., Ono K., Washizu T. Characterization of cDNA and the genomic sequence encoding canine neural-cell adhesion molecule, CD56/N-CAM. Vet. Immunol. Immunopathol. 2005, 107:171-176.
4. Carlens S., Gilljam M., Chambers B.J., Aschan J., Guven H., Ljunggren H.G., Christensson B., Dilber M.S. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum. Immunol. 2001, 62:1092-1098.
5. Dundon W.G., De Benedictis P., Viale E., Capua I. Serologic evidence of pandemic (H1N1) 2009 infection in dogs, Italy. Emerg. Infect. Dis. 2010, 16:2019-2021.
6. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J., Lockey T., Eldridge P., Leung W.H., Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009, 69:4010-4017.
7. Funk J., Schmitz G., Bach U., Failing K., Burkhardt E. Influence of different tumour types on natural cytotoxicity (NK cell activity) and mitogen-induced lymphocyte proliferation in isolated blood lymphocytes from 110 dogs with tumours. Res. Vet. Sci. 2003, 74:129-135.
8. Funk J., Schmitz G., Failing K., Burkhardt E. Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. Cancer Immunol. Immunother. 2005, 54:87-92.
9. Gagnier L., Wilhelm B.T., Mager D.L. Ly49 genes in non-rodent mammals. Immunogenetics 2003, 55:109-115.
10. Gondolf C., Burkhardt E., Failing K., Stitz L. A new colorimetric method for measuring cell-mediated cytotoxicity in dogs. Vet. Immunol. Immunopathol. 1996, 55:11-22.
11. Gyorffy S., Rodriguez-Lecompte J.C., Woods J.P., Foley R., Kruth S., Liaw P.C., Gauldie J. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J. Vet. Intern. Med. 2005, 19:56-63.
12. Hagglund H.G., McSweeney P.A., Mathioudakis G., Bruno B., Georges G.E., Gass M.J., Moore P., Sale G.E., Storb R., Nash R.A. Ex vivo expansion of canine dendritic cells from CD34+ bone marrow progenitor cells. Transplantation 2000, 70:1437-1442.
13. Halliwell R.E. Autoimmune disease in the dog. Adv. Vet. Sci. Comp. Med. 1978, 22:221-263.
14. Huang Y.C., Hung S.W., Jan T.R., Liao K.W., Cheng C.H., Wang Y.S., Chu R.M. CD5- low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. J. Leukoc. Biol. 2008, 84:1501-1510.
15. Iliopoulou E.G., Kountourakis P., Karamouzis M.V., Doufexis D., Ardavanis A., Baxevanis C.N., Rigatos G., Papamichail M., Perez S.A. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol. Immunother. 2010, 59:1781-1789.
16. Itoh H., Kakuta T., Kudo T., Sakonju I., Hohdatsu T., Ebina T., Takase K. Bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy. J. Vet. Med. Sci. 2003, 65:329-333.
17. Knapp D.W., Leibnitz R.R., DeNicola D.B., Turek J.J., Teclaw R., Shaffer L., Chan T.C. Measurement of NK activity in effector cells purified from canine peripheral lymphocytes. Vet. Immunol. Immunopathol. 1993, 35:239-251.
18. Knapp D.W., Turek J.J., DeNicola D.B., Chan T.C., Carter W.O., Snyder P.W., Robinson J.P. Ultrastructure and cytochemical staining characteristics of canine natural killer cells. Anat. Rec. 1995, 243:509-515.
19. Lin Y.C., Huang Y.C., Wang Y.S., Juang R.H., Liao K.W., Chu R.M. Canine CD8 T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules. Vet. Immunol. Immunopathol. 2010, 133:144-153.
20. Ljunggren H.G., Malmberg K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 2007, 7:329-339.
21. Loughran T.P., Deeg H.J., Storb R. Morphologic and phenotypic analysis of canine natural killer cells: evidence for T-cell lineage. Cell. Immunol. 1985, 95:207-217.
22. Lunemann A., Lunemann J.D., Munz C. Regulatory NK-cell functions in inflammation and autoimmunity. Mol. Med. 2009, 15:352-358.
23. Ma L.L., Wang C.L., Neely G.G., Epelman S., Krensky A.M., Mody C.H. NK cells use perforin rather than granulysin for anticryptococcal activity. J. Immunol. 2004, 173:3357-3365.
24. Mason N.J., Coughlin C.M., Overley B., Cohen J.N., Mitchell E.L., Colligon T.A., Clifford C.A., Zurbriggen A., Sorenmo K.U., Vonderheide R.H. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther. 2008, 15:955-965.
25. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., McKenna D., Le C., Defor T.E., Burns L.J., Orchard P.J., Blazar B.R., Wagner J.E., Slungaard A., Weisdorf D.J., Okazaki I.J., McGlave P.B. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
26. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., Biassoni R., Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 2001, 19:197-223.
27. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 2008, 8:147-156.
28. Paust S., Senman B., von Andrian U.H. Adaptive immune responses mediated by natural killer cells. Immunol. Rev. 2010, 235:286-296.
29. Raskin R.E., Tvedten H.W., Bull R.W., Crow S.E., Dunstan R.W., Krehbiel J.D. Natural killer cell activity in untreated and treated dogs with lymphoma. Am. J. Vet. Res. 1989, 50:483-487.
30. Ringler S.S., Krakowka S. Cell surface markers of the canine natural killer (NK) cell. Vet. Immunol. Immunopathol. 1985, 9:1-11.
31. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., Martelli M.F., Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
32. Schmitz G., Armien A.G., Fonfara S., Teifke J.P., Burkhardt E. Induction of apoptosis by canine natural killer cells. J. Vet. Med. A Physiol. Pathol. Clin. Med. 2003, 50:156-159.
33. Somanchi S.S., Senyukov V.V., Denman C.J., Lee D.A. Expansion, purification, and functional assessment of human peripheral blood NK cells. J. Vis. Exp. 2011, 48:2540-2544.
34. Spanholtz J., Preijers F., Tordoir M., Trilsbeek C., Paardekooper J., de Witte T., Schaap N., Dolstra H. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 2011, 6. e20740, 1-11.
35. Terme M., Ullrich E., Delahaye N.F., Chaput N., Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 2008, 9:486-494.
36. Vail D.M., MacEwen E.G. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000, 18:781-792.
37. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., Yokoyama W.M., Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
38. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008, 9:503-510.
39. Voskens C.J., Watanabe R., Rollins S., Campana D., Hasumi K., Mann D.L. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J. Exp. Clin. Cancer Res. 2010, 29:134.
40. Yasuda N., Masuda K., Tsukui T., Teng A., Ishii Y. Identification of canine natural CD3-positive T cells expressing an invariant T-cell receptor alpha chain. Vet. Immunol. Immunopathol. 2009, 132:224-231.